KR20090077806A - 결정질 피라졸로 [1,5-a]피리미딘 화합물의 제조방법 - Google Patents
결정질 피라졸로 [1,5-a]피리미딘 화합물의 제조방법 Download PDFInfo
- Publication number
- KR20090077806A KR20090077806A KR1020097008778A KR20097008778A KR20090077806A KR 20090077806 A KR20090077806 A KR 20090077806A KR 1020097008778 A KR1020097008778 A KR 1020097008778A KR 20097008778 A KR20097008778 A KR 20097008778A KR 20090077806 A KR20090077806 A KR 20090077806A
- Authority
- KR
- South Korea
- Prior art keywords
- temperature
- polymorph
- pyrazolo
- phenyl
- acetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (8)
- N-{2-플루오로-5-[3-(티오펜-2-카보닐)-피라졸로[1,5-a]피리미딘-7-일]-페닐}-N-메틸-아세트아미드의 다형체(B)의 산업적 제조 방법으로서, 상기 방법은,(i)(5-아미노-1H-피라졸-4-일)-티오펜-2-일-메타논을, N-[5-(3-디메틸아미노-아크릴로일)-2-플루오로-페닐]-N-메틸-아세트아미드와, 상기 혼합물의 50℃ 내지 끊는점 범위의 온도로 아세트산, 프로피오닌산 및 포름산으로 구성된 군으로부터 선택된 용매에서 반응시키고;(ⅱ) 메탄올, 에탄올, 2-프로판올, 또는 1-프로판올과 같은 (C1-C4)-알코올을 40℃ 내지 80℃의 온도에서 첨가하고;(ⅲ) 결정화를 시작하기 위해 30 내지 55℃의 온도에서 적어도 30분간 숙성시키며,(ⅳ) 상기 결정 생성물을 회수하는 것을 포함하는 N-{2-플루오로-5-[3-(티오펜-2-카보닐)-피라졸로[1,5-a]피리미딘-7-일]-페닐}-N-메틸-아세트아미드의 다형체 (B)의 산업적 제조방법.
- 제 1항에 있어서,단계(i)의 온도는 115℃ 내지 125℃인 것을 특징으로 하는 다형체(B)의 산업적 제조방법.
- 제 1항 내지 2항 중의 한 항에 있어서,상기 알코올은 2-프로판올이며, 이는 60℃ 내지 70℃의 온도에서 첨가되는 것을 특징으로 하는 다형체(B)의 산업적 제조방법.
- 제 1항 내지 3항 중의 한 항에 있어서,상기 숙성은 40℃ 내지 45℃의 온도에서 실행되는 것을 특징으로 하는 다형체(B)의 산업적 제조방법.
- 제 4항에 있어서,단계(ⅲ)의 숙성은 적어도 한 시간 발생하는 것을 특징으로 하는 다형체(B)의 산업적 제조방법.
- 제 1항 내지 5항 중의 한 항에 있어서,상기 결정 생성물은 0 내지 10℃의 온도에서 혼합물을 냉각하고, 획득된 생성물을 여과함에 의해 회수되는 것을 특징으로 하는 다형체(B)의 산업적 제조방법.
- 제 6항에 있어서,상기 혼합물은 여과 전에 적어도 1시간 동안 0-5℃의 온도에서 유지되는 것을 특징으로 하는 다형체(B)의 산업적 제조방법.
- 제 6항 내지 7항 중의 한 항에 있어서,상기 여과된 생성물은 45-55℃의 온도에서 건조되는 것을 특징으로 하는 다형체(B)의 산업적 제조방법.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85101106P | 2006-10-11 | 2006-10-11 | |
| EP06122143.8 | 2006-10-11 | ||
| US60/851,011 | 2006-10-11 | ||
| EP06122143A EP1956021A1 (en) | 2006-10-11 | 2006-10-11 | Process for the manufacture of a crystalline pyrazolo[1,5-a]pyrimidine compound |
| PCT/EP2007/060796 WO2008043799A1 (en) | 2006-10-11 | 2007-10-10 | Process for the manufacture of a crystalline pyrazolo[1,5-a]pyrimidine compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20090077806A true KR20090077806A (ko) | 2009-07-15 |
| KR101409573B1 KR101409573B1 (ko) | 2014-06-19 |
Family
ID=37808282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097008778A Expired - Fee Related KR101409573B1 (ko) | 2006-10-11 | 2007-10-10 | 결정질 피라졸로 [1,5-a]피리미딘 화합물의 제조방법 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8008486B2 (ko) |
| EP (2) | EP1956021A1 (ko) |
| JP (1) | JP5270555B2 (ko) |
| KR (1) | KR101409573B1 (ko) |
| CN (1) | CN101573362B (ko) |
| AR (1) | AR065831A1 (ko) |
| AT (1) | ATE503758T1 (ko) |
| AU (1) | AU2007306318B2 (ko) |
| BR (1) | BRPI0717836A2 (ko) |
| CA (1) | CA2664900C (ko) |
| CL (1) | CL2007002929A1 (ko) |
| DE (1) | DE602007013596D1 (ko) |
| DK (1) | DK2081934T3 (ko) |
| ES (1) | ES2362631T3 (ko) |
| MX (1) | MX2009003567A (ko) |
| NO (1) | NO342009B1 (ko) |
| PL (1) | PL2081934T3 (ko) |
| PT (1) | PT2081934E (ko) |
| RU (1) | RU2404984C1 (ko) |
| SI (1) | SI2081934T1 (ko) |
| TW (1) | TWI425000B (ko) |
| UY (1) | UY30619A1 (ko) |
| WO (1) | WO2008043799A1 (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1884516A1 (en) * | 2006-08-04 | 2008-02-06 | Ferrer Internacional, S.A. | Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399621B1 (en) * | 1999-08-10 | 2002-06-04 | American Cyanamid Company | N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto |
| DE60011638T2 (de) * | 1999-09-02 | 2004-10-21 | Neurocrine Biosciences Inc | POLYMORPHE DES N-METHYL-N-(3-(2-THIENYLCARBONYL)-PYRAZOL[1,5-a]PYRIMIDIN-7-YL PHENYL)ACETAMID UND ZUSAMMENSTELLUNGEN UND DIESBEZÜGLICHE METHODEN |
| SG125971A1 (en) * | 2000-08-03 | 2006-10-30 | Wyeth Corp | Variable water hydrates of zaleplon and method forthe preparation thereof |
| ATE343581T1 (de) * | 2002-08-26 | 2006-11-15 | Neurocrine Biosciences Inc | Polymorph von n-methyl-n-(3- 3- 2-[thienylcarbonylö-pyrazol-[1,5-alphaö-pyrimidin- - yl phenyl)acetamid und zusammensetzungen sowie verfahren hierzu |
| ES2222813B1 (es) | 2003-07-24 | 2005-12-16 | Ferrer Internacional, S.A. | N-(3-(3-sustituidas-pirazolo(1,5-a)pirimidin-7-il)-fenil)-sulfonamidas y composiciones y metodos relacionados. |
| US20060064488A1 (en) * | 2004-09-17 | 2006-03-23 | Ebert Robert F | Electronic software distribution method and system using a digital rights management method based on hardware identification |
| EP1736475A1 (en) * | 2005-06-21 | 2006-12-27 | Ferrer Internacional, S.A. | Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates |
-
2006
- 2006-10-11 EP EP06122143A patent/EP1956021A1/en not_active Withdrawn
-
2007
- 2007-09-28 TW TW096136170A patent/TWI425000B/zh not_active IP Right Cessation
- 2007-10-02 UY UY30619A patent/UY30619A1/es active IP Right Grant
- 2007-10-04 AR ARP070104402A patent/AR065831A1/es unknown
- 2007-10-10 PT PT07821163T patent/PT2081934E/pt unknown
- 2007-10-10 BR BRPI0717836-0A patent/BRPI0717836A2/pt not_active Application Discontinuation
- 2007-10-10 AU AU2007306318A patent/AU2007306318B2/en not_active Ceased
- 2007-10-10 EP EP07821163A patent/EP2081934B1/en not_active Not-in-force
- 2007-10-10 JP JP2009531842A patent/JP5270555B2/ja not_active Expired - Fee Related
- 2007-10-10 CA CA2664900A patent/CA2664900C/en not_active Expired - Fee Related
- 2007-10-10 WO PCT/EP2007/060796 patent/WO2008043799A1/en not_active Ceased
- 2007-10-10 CN CN2007800378352A patent/CN101573362B/zh not_active Expired - Fee Related
- 2007-10-10 RU RU2009117715/04A patent/RU2404984C1/ru not_active IP Right Cessation
- 2007-10-10 US US12/445,221 patent/US8008486B2/en not_active Expired - Fee Related
- 2007-10-10 MX MX2009003567A patent/MX2009003567A/es active IP Right Grant
- 2007-10-10 ES ES07821163T patent/ES2362631T3/es active Active
- 2007-10-10 DK DK07821163.8T patent/DK2081934T3/da active
- 2007-10-10 PL PL07821163T patent/PL2081934T3/pl unknown
- 2007-10-10 DE DE602007013596T patent/DE602007013596D1/de active Active
- 2007-10-10 SI SI200730614T patent/SI2081934T1/sl unknown
- 2007-10-10 AT AT07821163T patent/ATE503758T1/de active
- 2007-10-10 KR KR1020097008778A patent/KR101409573B1/ko not_active Expired - Fee Related
- 2007-10-11 CL CL200702929A patent/CL2007002929A1/es unknown
-
2009
- 2009-04-23 NO NO20091624A patent/NO342009B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20100101073A (ko) | 시타글립틴 및 약제학적으로 허용되는 그의 염의 제조 방법 | |
| JP2008239629A (ja) | 新規なベンラファクシン塩酸塩多型形状、ならびにその調製方法 | |
| JP2014513117A (ja) | アセナピンの結晶塩 | |
| WO2003011228A2 (en) | Purification and crystalline forms of zaleplon | |
| KR101409573B1 (ko) | 결정질 피라졸로 [1,5-a]피리미딘 화합물의 제조방법 | |
| HK1134924B (en) | Process for the manufacture of a crystalline pyrazolo[1,5-a]pyrimidine compound | |
| HK1130250B (en) | Process for the manufacture of a crystalline pyrazolo[1,5-a]pyrimidine compound | |
| JP4728548B2 (ja) | 光学活性アミノアルコールの製造方法 | |
| US20080108830A1 (en) | Production method of optically active 2-[(N-benzylprolyl)amino]benzo-phenone compound | |
| AU2004290695A1 (en) | Processes for the preparation of N-substituted phthalimides | |
| JP5156381B2 (ja) | N−メチル−N−(3−{3−[2−チエニルカルボニル]−ピラゾール−[1,5−α]−ピリミジン−7−イル}フェニル)アセトアミドの水和物ならびにそれに関連するプロセスおよび方法 | |
| EP1730153B1 (en) | Isopropanol water solvate of olanzapine | |
| WO2005023813A1 (en) | Zaleplon synthesis | |
| TW202547466A (zh) | 製造賽洛西賓(psilocybin)之可擴展方法 | |
| KR20260048580A (ko) | 2-[(3r)-2-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4[4-(옥세탄-3-일)피페라진-1-일]-펜트-2-엔니트릴및 이의 용매화물 형태의 제조 방법 | |
| RU2395488C1 (ru) | Способ получения фармацевтически приемлемых солей дес-глауцина | |
| TW202610622A (zh) | 2-(3,5-二氯-1-甲基-吲唑-4-基)-1-[(1s,3r)-3-(羥甲基)-5-(1-羥基-1-甲基-乙基)-1-甲基-3,4-二氫-1h-異喹啉-2-基]乙酮一水合物之製造方法 | |
| CN118076608A (zh) | [1,2,3]三唑并[4,5-d]嘧啶的合成 | |
| CN113620840A (zh) | 用于苯并茚前列腺素的中间物的晶体和其制备方法 | |
| AU2002329687A1 (en) | Purification and crystalline forms of zaleplon | |
| PL191924B1 (pl) | Sposób wytwarzania 4-chloro-3-sulfamoilo-N-(2-metylo-2,3-dihydro-1H-indol-1-ilo)benzamidu | |
| WO2009002955A1 (en) | Process for the preparation of (2r)-2-[4-(7-bromo-2-quinolyloxy)phenoxy]propanoic acid | |
| WO2005116044A1 (ja) | インドロピロロカルバゾール誘導体の製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
Fee payment year number: 1 St.27 status event code: A-2-2-U10-U12-oth-PR1002 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| FPAY | Annual fee payment |
Payment date: 20170530 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Fee payment year number: 4 St.27 status event code: A-4-4-U10-U11-oth-PR1001 |
|
| FPAY | Annual fee payment |
Payment date: 20180529 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Fee payment year number: 5 St.27 status event code: A-4-4-U10-U11-oth-PR1001 |
|
| FPAY | Annual fee payment |
Payment date: 20190531 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Fee payment year number: 6 St.27 status event code: A-4-4-U10-U11-oth-PR1001 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
Not in force date: 20200613 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE St.27 status event code: A-4-4-U10-U13-oth-PC1903 |
|
| PC1903 | Unpaid annual fee |
Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20200613 St.27 status event code: N-4-6-H10-H13-oth-PC1903 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |


